期刊文献+

Engineering customized nanovaccines for enhanced cancer immunotherapy

原文传递
导出
摘要 Nanovaccines have gathered significant attention for their potential to elicit tumor-specific immunological responses.Despite notable progress in tumor immunotherapy,nanovaccines still encounter considerable challenges such as low delivery efficiency,limited targeting ability,and suboptimal efficacy.With an aim of addressing these issues,engineering customized nanovaccines through modification or functionalization has emerged as a promising approach.These tailored nanovaccines not only enhance antigen presentation,but also effectively modulate immunosuppression within the tumor microenvironment.Specifically,they are distinguished by their diverse sizes,shapes,charges,structures,and unique physicochemical properties,along with targeting ligands.These features of nanovaccines facilitate lymph node accumulation and activation/regulation of immune cells.This overview of bespoke nanovaccines underscores their potential in both prophylactic and therapeutic applications,offering insights into their future development and role in cancer immunotherapy.
出处 《Bioactive Materials》 SCIE CSCD 2024年第6期330-357,共28页 生物活性材料(英文)
基金 financially supported by the National Key R&D Program of China(Grant No.2022YFB3808000/2022YFB3808001,Grant No.2021YFC2400600/2021 YFC2400604) the Medical Innovation Project of Science and Technology Program of Fujian Provincial Health Commission(Grant No.2021CXA006) the Project for High-Level Talent Innovation and Entrepreneurship of Quanzhou(Grant No.2022C016R) the Key Program of Qingyuan Innovation Laboratory(Grant No.00221002).
  • 相关文献

参考文献17

二级参考文献179

  • 1Ghiran I, Barbashov SF, Klickstein LB, et al. Complement receptor 1/CD35 is a receptor for mannan-binding lectin. J Exp Med 2000; 192:1797-1808.
  • 2Krych-Goldberg M, Atkinson JR Structure-function relationships of complement receptor type 1. Immunol Rev 2001; 180:112-122.
  • 3Bacle F, Haeffner-Cavaillon N, Laude M, Couturier C, Kazatchkine MD. Induction of IL-1 release through stimulation of the C3b/C4b complement receptor type one (CR1, CD35) on human monocytes. J Immunol 1990; 144:147-152.
  • 4Molina H, Kinoshita T, Webster CB, Holers VM. Analysis of C3b/C3d binding sites and factor I cofactor regions within mouse complement receptors 1 and 2. J Immunol 1994; 153:789-795.
  • 5Ross GD. Regulation of the adhesion versus cytotoxic functions of the Mac-1/CR3/alphaMbeta2-integrin glycoprotein. Crit Rev Immunol 2000; 20:197-222.
  • 6Helmy KY, Katschke KJ Jr, Gorgani NN, et al. CRIg: a macrophage complement receptor required for phagocytosis of circulating pathogens. Cell 2006; 124:915-927.
  • 7Nussenzweig V, Bianco C, Dukor P, Eden A. Progress in Immunology. New York: Academic, 1971.
  • 8Pepys MB. Role of complement in induction of the allergic response. Nat New Biol 1972; 237:157-159.
  • 9Ochs HD, Wedgwood R J, Heller SR, Beatty PG. Lompiemem, membrane glycoproteins, and complement receptors: their role in regulation of the immune response. Clin Immunol Immunopathol 1986; 40:94-104.
  • 10O'Neil KM, Ochs HD, Heller SR, et al. Role of C3 in humoral immunity. Defective antibody production in C3-deficient dogs. J Immunol 1988; 140:1939-1945.

共引文献348

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部